What was the total compensation for the CEO in 2011 and what is his base salary for 2012?

For the fiscal year 2011, John C. Martin, Chairman and Chief Executive Officer, received a bonus of $2,788,500. His base salary for the 2012 fiscal year was set at $1,500,000.

How are the performance share awards structured and what metrics are used for vesting?

The performance share awards are divided into two equal tranches. The first tranche's vesting is tied to Gilead's total shareholder return over a three-year period relative to specific S&P Healthcare Index sub-groups. The second tranche is further divided into three sub-tranches, each linked to the company's revenue recognition for the 2012, 2013, and 2014 calendar fiscal years, respectively. Vesting for all tranches also requires continued service with the company through specified periods.

What is the potential upside for executive officers through the performance share awards?

The performance share awards allow for the number of shares into which performance shares convert to range from 0% to 200% of the allocated number, based on the attainment of pre-established performance goals. This means executives can potentially double the target number of shares awarded if performance targets are met or exceeded.

What happens to equity awards in the event of a change in control?

In the event of a change in control transaction, and provided the executive officer remains in continued service through the closing, a portion of their performance shares allocated to service periods that have commenced will immediately convert into vested shares. The specific percentage can be 100% of the allocated shares, or potentially a higher percentage for the first tranche if the change in control occurs more than one year into the performance period, based on an abbreviated performance assessment.

GILD 8-K: Leadership Changes

Summary

This Form 8-K filing by Gilead Sciences, Inc. (GILD) on February 1, 2012, reports on compensation arrangements for its named executive officers, specifically detailing 2011 bonus awards and 2012 base salaries, as well as new equity awards granted on January 26, 2012. The information is primarily focused on the compensation structure for key leadership personnel as determined by the Compensation Committee of the Board of Directors. Investors should note the significant bonus payouts for 2011 and the established base salaries for 2012, which provide a baseline for executive compensation. Furthermore, the company granted stock options and performance share awards designed to align executive incentives with long-term company performance and shareholder value. The performance share awards are tied to specific metrics like total shareholder return and revenue recognition over multi-year periods, indicating a strategic focus on sustained growth and market competitiveness.

Key Highlights

1Gilead Sciences' Compensation Committee set 2012 base salaries and awarded 2011 bonuses to its named executive officers.
2John C. Martin, CEO, received a 2011 bonus of $2,788,500 and a 2012 base salary of $1,500,000.
3New equity awards, including stock options and performance share awards, were granted to executive officers on January 26, 2012, under the 2004 Equity Incentive Plan.
4Stock options have an exercise price of $48.59 and vest over four years, with 25% vesting after the first anniversary.
5Performance share awards are structured into two tranches with vesting tied to total shareholder return relative to the S&P Healthcare Index and company revenue targets over multi-year periods (2012-2014).
6The maximum number of shares an executive can receive from performance awards is double the target number, contingent on achieving performance goals.
7Provisions for forfeiture, pro-rated awards upon retirement, death, or disability, and accelerated vesting upon a change in control are outlined for performance share awards.

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Feb 1, 2012)

Summary

Key Highlights

Frequently Asked Questions